Atelerix Ltd
5 News & Press Releases found

Atelerix Ltd news

Peripheral blood mononuclear cells (PBMCs), derived from whole blood or leukapheresis, encompass several major immune cell populations including lymphocytes, monocytes, NK cells and dendritic cells. Apheresis material is a PBMC-enriched blood product widely used in cell therapy, the maximum shelf life of which is 48h when supplied fresh. The collection, processing, and shipment of fresh apheresis material must therefore by rigorously controlled to ensure optimal cell quality and perform

Feb. 9, 2023

New distributor agreement between Atelerix (UK) and BioBench Solutions LLP (India).

We are proud to announce the beginning of a new distribution agreement with BioBench Solutions, who will be distributing our products across Indian.

Our global customer base is growing rapidly due to problems associated with cryogenics, the vast increase in the use of complex physiologically relevant cell models in drug discovery, and our movement towards the regulated market o

Sep. 7, 2022

Atelerix has received notification that its newest patent application has been published pertaining to the STORING AND/OR TRANSPORTING OF EXTRACELLULAR NUCLEIC ACIDS (WO 2022/101640). This application was made after the surprising observation that Atelerix’s hydrogel-encapsulation technology (in the form of SwabReady™) was able to extend the shelf life of free Coronavirus samples when stored at room temperature. Whilst in conventional viral transport medium viral function

Aug. 29, 2022

Atelerix Ltd (Atelerix) announces the appointment of a new CEO as the company accelerates its growth programme. Over the last four years, the company has been led by co-founder and CEO, Mick McLean, as it developed its products and started commercialisation of its innovative cell encapsulation technology. Mick is now stepping back for personal reasons but will continue supporting the company as a Non-Executive Director.

Edwin Wagena, currently serving as the Chief Operating Officer of

Jan. 6, 2021

CELLINK and Atelerix announced today a partnership to bring to market Atelerix’s portfolio of innova­tive hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature. Conven­tional shipping methods often involve storing cells and tissues in liquid nitrogen or dry ice, which requires a freeze-thaw process notorious for damaging biological material. Therefore, the global bioprinting community will greatly benefit fro

Dec. 4, 2020